Clinical trials: Intractable Epilepsy
Epilepsy, Lennox Gastaut Syndrome
RNS System LGS Feasibility Study
To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or…
- Conditions
- Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures
- Trial name
- NCT05339126
- Testing
- RNS System
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- NeuroPace
Epilepsy, Alzheimer Disease
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
- Conditions
- Epilepsy, Alzheimer Disease, Epilepsy Intractable
- Trial name
- NCT07222878
- Testing
- NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NeuroPro Therapeutics, Inc.
Intractable Epilepsy, Glucose Transporter Type 1 Deficiency Syndrome
Evaluation of Keyo in Children With Epilepsy
To evaluate the tolerance, acceptability and compliance of Keyo in 20 subjects aged 3 years and over, with intractable epilepsy or Glut-1 DS on a KD.
- Conditions
- Intractable Epilepsy, Glucose Transporter Type 1 Deficiency Syndrome, Ketogenic Dieting
- Trial name
- Keyo (NCT02915211)
- Testing
- Keyo
- Where
- 2 sites in United Kingdom
- Volunteers
- 17 people
- Sponsor
- Vitaflo International, Ltd
Epilepsy Intractable, Glucose Transporter Type 1 Deficiency Syndrome
Evaluation of Ketoflo
For 28 days, 30 participants aged 3 to 18 years of age (inclusive) with a condition requiring a ketogenic diet will incorporate Ketoflo into their usual dietary regime.
- Conditions
- Epilepsy Intractable, Glucose Transporter Type 1 Deficiency Syndrome, Ketogenic Dieting
- Trial name
- Ketoflo (NCT04399954)
- Testing
- Ketoflo
- Where
- 5 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- Vitaflo International, Ltd
Epilepsy, Alzheimer Disease
Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects
Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.
- Conditions
- Epilepsy, Alzheimer Disease, Epilepsy Intractable
- Trial name
- NCT05503511
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- NeuroPro Therapeutics, Inc.
Intellectual Disability, Developmental Delay
Biomarker for Creatine Deficiency Syndromes (BioCDS)
Development of a new mass spectrometry-based biomarker for the ear-ly and sensitive diagnosis of the Creatine Deficiency Syndromes from dry-blood-spot sample
- Conditions
- Intellectual Disability, Developmental Delay, Movement Disorder, Behavioral Disorder
- Trial name
- BioCDS (NCT02934854)
- Where
- 4 sites in Egypt, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Drug Resistant Epilepsy, Epilepsy, Drug Resistant
Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy
This study is to evaluate the safety and the intracranial electroencephalography (iEEG) changes of using NaviFUS System for the treatment of patients with drug resistant epilepsy.
- Conditions
- Drug Resistant Epilepsy, Epilepsy, Drug Resistant, Drug Refractory Epilepsy, Epilepsy, Drug Refractory
- Trial name
- NCT03860298
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- NaviFUS Corporation
Intractable Epilepsy
Ketogenic Diet Drink Study
An evaluation of the tolerance, compliance, acceptability and safety of a nutritionally complete liquid feed for use as part of the ketogenic diet (KD) in children 8+ years, adolescents and adults with intractable epilepsy or…
- Trial name
- NCT03196271
- Testing
- Ketocal 2.5:1
- Where
- 9 sites in United Kingdom
- Volunteers
- 26 people
- Sponsor
- Nutricia UK Ltd
Epilepsy Intractable
A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy
To evaluate the safety, tolerability and efficacy of oral administration of PTL101 (cannabidiol) for the treatment for pediatric intractable epilepsy.
- Trial name
- NCT02987114
- Testing
- PLT101
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- PhytoTech Therapeutics, Ltd.